- Home
- GKOS vs HAS Comparison
GKOS vs HAS Comparison
Compare GKOS & HAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- HAS
- Stock Information
- Founded
- GKOS 1998
- HAS 1923
- Country
- GKOS United States
- HAS United States
- Employees
- GKOS N/A
- HAS N/A
- Industry
- GKOS Medical/Dental Instruments
- HAS Recreational Games/Products/Toys
- Sector
- GKOS Health Care
- HAS Consumer Discretionary
- Exchange
- GKOS Nasdaq
- HAS Nasdaq
- Market Cap
- GKOS 5.1B
- HAS N/A
- IPO Year
- GKOS 2015
- HAS N/A
- Fundamental
- Price
- GKOS $96.63
- HAS $60.99
- Analyst Decision
- GKOS Strong Buy
- HAS Strong Buy
- Analyst Count
- GKOS 13
- HAS 9
- Target Price
- GKOS $155.00
- HAS $79.56
- AVG Volume (30 Days)
- GKOS 1.0M
- HAS 2.5M
- Earning Date
- GKOS 04-30-2025
- HAS 04-24-2025
- Dividend Yield
- GKOS N/A
- HAS 4.59%
- EPS Growth
- GKOS N/A
- HAS N/A
- EPS
- GKOS N/A
- HAS 3.03
- Revenue
- GKOS $383,481,000.00
- HAS $4,265,300,000.00
- Revenue This Year
- GKOS $27.84
- HAS $1.54
- Revenue Next Year
- GKOS $27.99
- HAS $5.17
- P/E Ratio
- GKOS N/A
- HAS $20.15
- Revenue Growth
- GKOS 21.85
- HAS N/A
- 52 Week Low
- GKOS $77.91
- HAS $49.00
- 52 Week High
- GKOS $163.71
- HAS $73.46
- Technical
- Relative Strength Index (RSI)
- GKOS 50.06
- HAS 60.29
- Support Level
- GKOS $87.17
- HAS $50.55
- Resistance Level
- GKOS $98.86
- HAS $52.97
- Average True Range (ATR)
- GKOS 5.59
- HAS 2.99
- MACD
- GKOS 1.78
- HAS 0.96
- Stochastic Oscillator
- GKOS 88.89
- HAS 93.34
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.